Enviro Tech, an Arxada Company, Launches Patented Breakthrough Technology for On-Site Generation of Peracetic Acid (PAA)

October 9, 2025 8:00 AM

Enviro Tech, an Arxada company, is proud to announce the launch of a patented breakthrough technology for the on-site generation of peracetic acid (PAA)-a game-changing innovation for several end-use markets, including poultry processing and other food safety applications.This technology, paired with ChemStation's unique blending and feed system, enables fully automated production of a ready-to-use PAA solution. This combined solution offers...

Read more

Lobe Sciences Improves Balance Sheet

October 9, 2025 6:50 AM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapies through a scalable model of shared services, global teams, and outsourced infrastructure. The Company creates intellectual property, packages it into subsidiaries, and advances each toward clinical and commercial milestones.The Company is pleased to announce the proposed settlement of USD 137,130...

Read more

Alligator Announces Publication of OPTIMIZE-1 Biomarker Analysis in Cell Reports Medicine Supporting mitazalimab and mFOLFIRINOX in Metastatic Pancreatic Cancer

October 8, 2025 3:00 AM

Alligator Bioscience (Nasdaq Stockholm: ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced the publication of a peer-reviewed article in Cell Reports Medicine, a Cell Press journal. The paper presents biomarkers associated with clinical efficacy endpoints from the Phase 1b/2 OPTIMIZE-1 trial evaluating Alligator's CD40 agonist mitazalimab in combination with...

Read more

BioInvent Announces Initiation of BI-1206 Phase 2a Trial in Advanced or Metastatic NSCLC and Uveal Melanoma

October 8, 2025 2:15 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced the initiation of a Phase 2a clinical trial evaluating BI-1206 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced or metastatic...

Read more

ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles

October 7, 2025 4:15 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced results from a Phase I-II clinical study at Skåne University Hospital in Lund, Sweden evaluating the ClearPoint Prism Neuro Laser Therapy System's safety, feasibility, and efficacy. The study cohort comprised fourteen patients ages 18-80years with primary and recurrent...

Read more

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

October 7, 2025 11:00 AM

Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) is quietly redrawing the boundaries of what a biotechnology company can be. The company has evolved beyond traditional R&D into a diversified enterprise-one that integrates clinical innovation, consumer health commercialization, and advanced market infrastructure.In an era where science, data, and capital efficiency intersect, Quantum BioPharma represents a new category of public issuer:...

Read more

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

October 7, 2025 9:00 AM

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced in-vitro findings for IGC-1C, a low-molecular weight compound. The data are consistent with IGC-1C acting as a modulator of the tau protein's liquid-liquid phase separation (LLPS), an emerging and critical pathway implicated in the earliest...

Read more

ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide

October 6, 2025 4:10 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced several expanded regulatory approvals for product use in Canada, Hong Kong, and Taiwan. This most recent batch of strategically selected geographical clearances establishes a total of 34 countries worldwide in which BioPharma partners will have a reliable and familiar...

Read more

BrYet US, Inc. Receives Approval to Initiate in Australia a First-in-Human Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement

October 6, 2025 10:20 AM

HOUSTON, TX and SUNSHINE COAST, QUEENSLAND / ACCESS Newswire / October 6, 2025 / BrYet US, Inc. ("BrYet"), a biotechnology innovator developing a drug with the potential to be a first-in-class medicine for metastatic disease, today announced that it has received an Australian Human Research Ethics Committee (HREC) approval for its first-in-human clinical study of ML-016.The open-label, dose-escalation and expansion study, titled "A Phase 1/2...

Read more

Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline

October 6, 2025 9:15 AM

Lunai Bioworks (Nasdaq:LNAI) today announced a major advance in Alzheimer's research: its AI platform, Augusta™, achieved up to a 35% improvement in diagnostic accuracy by combining MRI scans with genetic and metabolic data. The company is launching a preclinical Alzheimer's program to bring this technology closer to clinical use, a move that could enable earlier intervention for millions worldwide.The new program builds on Lunai's recent...

Read more

Alligator Bioscience Announces Acceptance of Two Abstracts at SITC 40th Anniversary Annual Meeting

October 6, 2025 9:15 AM

Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, to be held 7-9 November 2025 in National Harbor, MD, USA.The presentations will feature new data from Alligator's pipeline programs mitazalimab and...

Read more

BioInvent to Present Phase 1 Clinical Data for BI-1910, a TNFR2 Agonist for the Treatment of Solid Tumors, at SITC

October 3, 2025 9:15 AM

BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, will present a poster with data from its trial of BI-1910 at the upcoming SITC Annual Meeting. The abstract title, which was released today, is "Preliminary Phase 1 results of clinical trial investigating BI-1910, a Tumor Necrosis...

Read more

ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System

October 1, 2025 4:05 PM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today formally announced the development and demonstration of the Company's proprietary Robotic Neuro-Navigation System. This new product category will enable the ClearPoint Neuro Navigation software to operate the KUKA LBR Med Robotic Arm to support all minimally invasive cranial...

Read more

Coeptis Anchors $800M Valuation in Dual-Sector Strategy; Vanderbilt Report Publishes Coverage

October 1, 2025 8:07 AM

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) today announced that The Vanderbilt Report has published coverage of the company following its recent SEC filings.According to disclosures filed on January 31, 2025, Coeptis' technology division was assigned a $660.3 million fair market value. In addition, management has outlined a planned biotech spin-out, valued at approximately $75 million, together with tax advantages that may support future...

Read more

Biolog Lab Services Enters Food Safety Arena to Combat Pathogen Risks

October 1, 2025 6:00 AM

Biolog, Inc., a trusted leader in microbial identification and testing, today announced its new Foodborne Pathogen Testing Service, out of it's Newark, Delaware location, expanding its portfolio to include ISO-certified molecular assays that safeguard food safety and support regulatory compliance for food producers of all sizes.The new service delivers rapid, scientifically validated detection across various matrices for the five most common...

Read more

Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees

September 30, 2025 4:10 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that two of its senior leaders - CCO Damien Perriman and VP of Development, Dr. Paul Opgenorth - have been elected to key roles within the BioMADE Governance Committees.Chief Commercial Officer at eXoZymes, Damien Perriman, states, "Being elected to...

Read more

Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense

September 30, 2025 9:15 AM

Lunai Bioworks Inc. (Nasdaq:LNAI), a pioneer in AI-powered drug discovery and biodefense, today announced the formal adoption of its new corporate identity, reflecting a sharpened strategic focus and a streamlined capital structure following a 10:1 reverse stock split.The rebranding from Renovaro Inc. to Lunai Bioworks marks a pivotal evolution in the company's mission: to capture biological signals at scale, decode them using AI, and validate...

Read more

Buloxibutid Receives Orphan Drug Designation in Japan for the Treatment of Idiopathic Pulmonary Fibrosis

September 30, 2025 2:50 AM

Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Drug designation to buloxibutid for the treatment of idiopathic pulmonary fibrosis (IPF).Buloxibutid is a first-in-class angiotensin II type 2 receptor agonist that activates an upstream mechanism to drive alveolar...

Read more

Astraglass Innovations and Scalables Partner to Launch AI-Powered, Modular Bioreactor Platform

September 29, 2025 12:10 PM

Astraglass Innovations, a leading North American manufacturer of precision scientific glassware, and Scalables, the pioneer behind the Daisy modular lab-automation platform, announced a strategic collaboration to deliver a next-generation bioreactor system that combines Astraglass's advanced vessels with Scalables' AI-driven controller technology.This AI-enabled, modular bioreactor platform is designed to help pharmaceutical and biotechnology...

Read more

Neurovation Labs Joins NewYorkBIO Fellows Program to Accelerate Development of Biomarker-Driven Neuromedicines and Diagnostics

September 29, 2025 11:25 AM

Neurovation Labs, Inc., a precision neuroscience biotechnology company targeting physiological biomarkers of central nervous system (CNS) disorders for comprehensive diagnosis and treatment, today announced its acceptance to the NewYorkBIO Fellows Program, an initiative that provides emerging biotech companies with extensive resources, networks, and opportunities to accelerate innovation and improve patient outcomes."Acceptance into the...

Read more